

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 1 046 630 B1

(12)

EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention
of the grant of the patent:

19.03.2003 Bulletin 2003/12

(51) Int Cl.7: **C07C 51/43, C07C 57/03**

(21) Application number: **00108675.0**

(22) Date of filing: **20.04.2000**

(54) **Method of purification of 3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid**

Verfahren zur Reinigung von 3,7,11,15-Tetramethyl-2,4,6,10,14-hexadecapentaensäure

Procédé de purification de l'acide 3,7,11,15-tétraméthyle-2,4,6,10,14-hexadécapentaénoïque

(84) Designated Contracting States:
CH DE FR GB IE IT LI

(30) Priority: **23.04.1999 JP 11648399**

(43) Date of publication of application:
25.10.2000 Bulletin 2000/43

(73) Proprietor: **Nikken Chemicals Company, Limited**
Tokyo 104-0045 (JP)

(72) Inventors:

- **Takano, Michika,**
c/o Omiya Research Laboratory
Omiya-shi, Saitama 330-0835 (JP)
- **Gomi, Noriaki, c/o Omiya Research Laboratory**
Omiya-shi, Saitama 330-0835 (JP)

(74) Representative:

Sternagel, Fleischer, Godemeyer & Partner
Patentanwälte
An den Gärten 7
51491 Overath (DE)

(56) References cited:

WO-A-94/22818 **GB-A- 781 809**
US-A- 4 757 140

- **ASHIZAWA, K. ET AL: "The Crystal Structure of**
3,7,11,15-tetramethyl-2,4,6,10,14-all
trans-hexadecapentaenoic acid" CHEM.
PHARM. BULL, vol. 33, no. 7, 1985, pages
3062-3064, XP002144911

EP 1 046 630 B1

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

Description

Field of the Invention

- 5 [0001] The present invention relates to a method for purification of the polyprenyl compounds 3, 7, 11, 15 tetramethyl-2,4,6,10,14-hexadeca pentaenoic acid.

Related Art

- 10 [0002] (2E,4E,6E,10E)-3,7,11,15-Tetramethyl-2,4,6,10,14-hexadecapentaenoic acid, which is one of polyprenyl compounds, has been known to have suppressing effect on recurrence of hepatic carcinoma (New England Journal of Medicine, 334, 1516 (1996)).


- [0003] The crystal structure of the compound is described in Ashizawa, K. et. al: The crystal structure of 3,7,11,15-tetramethyl-2,4,6,10,14-all trans-hexadeca pentaenoic acid, Chem. Pharm. Bull., vol. 33, no. 7, 1985, p. 3062-3064. The single crystal was obtained by recrystallisation from acetonitrile.

- 15 [0004] Polyprenyl compounds are a known class of compounds as disclosed in Japanese Patent Publication (Kokoku) Nos. 63-32058, 63-34855 and the like. As described in the above patent publications, a purification method for polyprenyl compounds is known which comprises the step of subjecting crude crystals of polyprenyl compounds obtained by a reaction to crystallization and recrystallization in n-hexane.

SUMMARY OF THE INVENTION

- 20 [0005] The conventional purification of polyprenyl compounds using n-hexane fails to completely remove impurities produced during or after the reaction. The inventors of the present invention eagerly conducted researches on purification of polyprenyl compounds that are susceptible to oxidization with light, air and the like. As a result, they found that peroxides or oxides, which were not completely removable by the treatment using n-hexane, were perfectly removed by stirring a crude polyprenyl compound in an alcoholic solvent such as methanol for several hours with warming, and then carrying out recrystallization. They also found that a target polyprenyl compound of an extremely high purity was obtained by the above procedure. The present invention was achieved on the basis of these findings.

- 30 [0006] The present invention thus provides a method for purification of a polyprenyl compound, which comprises the step of recrystallizing 3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid preferably (2E,4E,6E,10E)-3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid represented by Formula (I), by using a solvent comprising essentially an alcohol.



- [0007] According to preferred embodiments of the present invention, there are provided:

- 45 the aforementioned method for purification of a polyprenyl compound, wherein the solvent is essentially an alcohol, preferably methanol; and
the aforementioned method for purification of a polyprenyl compound, wherein a purity of the polyprenyl compound after the purification step is 99.9% or higher.

PREFERRED EMBODIMENTS OF THE INVENTION

- 50 [0008] A particularly preferred example of the polyprenyl compound which can be purified by the method of the present invention includes (2E,4E,6E,10E)-3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid whose chemical formula is shown above. Other examples of the polyprenyl compounds include conjugated polyprenylcarboxylic acids (polyprenoic acids) such as 3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid.

- 55 [0009] The polyprenyl compounds used in the present invention can be synthesized by a known method disclosed in Japanese Patent Publication (Kokoku) No. 63-32058 and Journal of Chemical Society (C), 2154, 1966.

- [0010] The recrystallization using a solvent consisting essentially of an alcohol is performed by recrystallizing crude crystals of a polyprenyl compound, or by recrystallizing crystals of a polyprenyl compound of a relatively high purity.

As the alcoholic solvent used for the recrystallization, examples include methanol, ethanol, 1-propanol, 2-propanol, 1-butanol, 2-butanol, 3-methylpropanol, 3-methyl-1-butanol and the like, and among them, methanol is preferably used. In addition, a solvent containing an alcohol such as methanol and ethanol can also be used for the present invention. Examples of a solvent which can be used as a mixture or a suspension with an alcohol include, for example, halogenated solvents such as carbon tetrachloride, chloroform and dichloromethane, hydrocarbonic solvents such as n-pentane, n-hexane, n-heptane, isooctane, cyclohexane, methylcyclohexane, toluene, benzene and xylene, ether solvents such as diethyl ether, diisopropyl ether, t-butyl methyl ether, methyltetrahydrofuran, tetrahydrofuran, 1,4-dioxane, 1,1-diethoxypropane, 1,1-dimethoxymethane and 2,2-dimethoxypropane, ester solvents such as ethyl acetate and ethyl formate, other organic solvents such as acetonitrile, N,N-dimethylacetamide, N,N-dimethylformamide, dimethyl sulfoxide, acetone, methyl ethyl ketone, methyl isopropyl ketone, petroleum ether, and water.

[0011] The recrystallization according to the present invention is performed by dissolving a polyprenyl compound in a solvent consisting essentially of an alcohol, preferably an alcoholic solvent such as methanol and ethanol, most preferably methanol, and then cooling the solution to allow precipitation of crystals.

[0012] Specifically, a solvent comprising essentially an alcohol is added to a polyprenyl compound, and the mixture is stirred within a temperature ranging from room temperature to a boiling temperature of the solvent consisting essentially of an alcohol under heating. Then, the solution is left stand to allow precipitation of crystals.

[0013] More specifically, when methanol is used as the solvent consisting essentially of an alcohol, the solution is warmed to generally 50 to 70°C, preferably about 60°C, and stirred generally for about 1 hour or more, preferably about 3 hours. Then, the solution is left stand for cooling to allow precipitation of crystals.

[0014] By carrying out the purification of the present invention, a high purity of 99.9% or higher can be obtained for (2E,4E,6E,10E)-3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid and the like. One of advantages of the high purity of the compound obtained by the present invention may include the following. Namely, for a government approval of the manufacture of a new drug, structural determination, and evaluation of toxicity and pharmacological action as well as normalization of a product are required for an impurity contained at a content ratio of 0.1% or more. Therefore, the process of obtaining a highly purified compound by the purification of the present invention is useful to obtain a drug with an excellent quality,

EXAMPLES

[0015] The present invention will be explained more specifically with reference to examples. However, the scope of the present invention is not limited to the following examples.

Reference Example 1

(2E,4E,6E,10E)-3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid ethyl ester

[0016] Under argon atmosphere, sodium ethoxide (18.1 g) was suspended in N,N-dimethylformamide (200 ml), and the suspension was added dropwise with triethyl-3-methyl-4-phosphonocrotonate (purity: 80%, 58.4 g) dissolved in N,N-dimethylformamide (50 ml) at a low temperature. The reaction mixture was stirred at room temperature for 20 minutes, and then added dropwise with trans, trans-farnesal (37.1 g) dissolved in N,N-dimethylformamide (50 ml) on an ice bath. The mixture was stirred for 4 hours, then added with ice water and acetic acid, and extracted with n-hexane under a weakly acidic condition. After the extraction, the n-hexane layer was washed with 75% aqueous methanol and then with brine, and dried over magnesium sulfate. The solvent was evaporated under reduced pressure to obtain (2E,4E,6E,10E)-3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid ethyl ester (48.6 g).

Reference Example 2

(2E,4E,6E,10E)-3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid

[0017] Under argon atmosphere, potassium hydroxide (19.4 g) was dissolved in 2-propanol (200 ml) under reflux, and the solution was added dropwise with (2E,4E,6E,10E)-3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid ethyl ester (48.6 g) dissolved in 2-propanol (50 ml). After the mixture was stirred for 10 minutes under reflux, ice water was added to the reaction mixture and the aqueous layer was washed with n-hexane. The aqueous layer was made acid with 10% aqueous hydrochloric acid, and then extracted with diisopropyl ether. The organic layer was washed with brine and dried over magnesium sulfate, and the solvent was evaporated under reduced pressure to obtain crude (2E,4E,6E,10E)-3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid (35.7 g, purity: 62.2%) as orange crystals.

Example 1

[Purification of (2E,4E,6E,10E)-3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid]

- 5 [0018] Under argon atmosphere, methanol (35 ml) was added to the crude (2E,4E,6E,10E)-3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid (17.8 g) obtained in Reference Example 2, and the crystals were dissolved with warming. The solution was left stand overnight at an external temperature of -20°C to allow precipitation of crystals. The deposited crystals were collected by filtration to obtain roughly purified (2E,4E,6E,10E)-3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid (6.9 g, purity: 94.5%) as yellow crystals. Subsequently, the roughly purified product
- 10 was added with methanol (15 ml), and the solution was maintained at 60°C for 3 hours with stirring under argon atmosphere. The mixture was left stand at room temperature, and the deposited crystals were collected by filtration to obtain (2E,4E,6E,10E)-3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid (5.8 g) as light yellow crystals.
- ¹H-NMR(CDCl₃) : δ 1.60 (s, 3H), 1.61 (s, 3H), 1.68 (s, 3H), 1.86 (s, 3H), 1.96-2.09 (m, 4H), 2.15 (s, 2H), 2.16 (s, 2H), 2.34 (s, 3H), 5.06-5.10 (m, 2H), 5.77 (s, 1H), 5.98 (d, 1H, J=11.2Hz), 6.20 (d, 1H, J=15.1Hz), 6.90 (dd, 1H, J=11.2,
- 15 15.1Hz), 11.8 (br, 1H)
- ¹³C-NMR(CDCl₃) : δ 14.2, 16.2, 17.4, 17.8, 25.8, 26.5, 26.8, 39.8, 40.4, 117.1, 123.3, 124.1, 124.8, 131.2, 131.8, 133.1, 135.5, 144.6, 155.4, 172.3
- Melting point: 78°C

20 Reference Example 3

[Purification of (2E,4E,6E,10E)-3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid by a conventional method]

- 25 [0019] The crude (2E,4E,6E,10E)-3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid (17.8 g) obtained in Reference Example 2 was dissolved in n-hexane (35 ml) with warming, and the solution was left stand overnight at an external temperature of -20°C to allow the precipitation of crystals. The deposited crystals were collected by filtration to obtain roughly purified (2E,4E,6E,10E)-3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid (6.3g, purity: 94.4%) as yellow crystals. The roughly purified product was recrystallized from n-hexane (15 ml) to obtain (2E,4E,6E,
- 30 10E)-3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid (5.6 g, purity: 99.2%) as light yellow crystals.

Reference Example 4

- 35 [Re-purification of (2E,4E,6E,10E)-3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid by conventional method]

- [0020] The (2E,4E,6E,10E)-3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid (3 g, purity of 99.2%) purified in Reference Example 3 was dissolved in n-hexane (6 ml) with warming, and the solution was left stand at room temperature to allow the precipitation of crystals. The deposited crystals were collected by filtration to obtain (2E,4E,
- 40 6E,10E)-3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid (2.8 g, yield: 93%) as light yellow crystals.

Test Example 1

- 45 [0021] The results of purities and determined peroxide values of (2E,4E,6E,10E)-3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid obtained in Example 1 and Reference Example 3 are shown in Table 1.
- [0022] Purities were measured by high performance liquid chromatography.
- [0023] The determination of the peroxide values was performed by the method described in the British Pharmacopeia. About 1 g of each sample was accurately weighed in a stoppered Erlenmeyer flask, and the sample was added with chloroform (15 mL) and dissolved. The solution was added with acetic acid (20 mL), and the mixture was shaken gently.
- 50 Air in the flask was sufficiently substituted with argon atmosphere, and the mixture was added with 1 mL of saturated potassium iodide solution prepared just before use, and the mixture was left stand for 10 minutes in a dark place. Then, the mixture was added with 30 mL of water and shaken vigorously. The liberated iodine was titrated with 0.01 mL/L sodium thiosulfate solution (indicator: 2 mL of the starch test solution). The titration was terminated when the purplish red color of the solution disappeared. Correction was made by performing a blank test in the same manner.
- 55 [0024] The peroxide value was calculated by using the following equation.

$$\text{Peroxide value (meq/kg)} = 10f(a-b)/\text{Sampled weight (g)}$$

a: Titration volume (mL) of 0.01 mol/L $\text{Na}_2\text{S}_2\text{O}_3$ solution

b: Titration volume (mL) of 0.01 mol/L $\text{Na}_2\text{S}_2\text{O}_3$ solution in the blank test

f: Factor of 0.01 mol/L $\text{Na}_2\text{S}_2\text{O}_3$ solution

Table 1

Sample	Purity before crystallization (%)	Purity of roughly purified product (%)	Purity after recrystallization (%)	Peroxide value (meq/kg)
Reference Example 3	62.2	94.4	99.2	3.0
Example 1		94.5	99.9	0

[0025] From the results shown in Table 1, as well as from the amounts (yields) and the purities of the target compound obtained in Example 1 and Reference Example 3, it is apparent that the purification by using an alcohol such as methanol according to the present invention can give a purity of 99.9% or higher of the target compound and achieve complete removal of peroxides (give peroxide value of 0), while the purification can give almost the same recovery rate of the target compound as the purification by the conventional method.

Test Example 2

[0026] Purity of the (2E,4E,6E,10E)-3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid obtained in Reference Example 4 was determined as 99.5% (the purity of 99.2% was improved up to 99.5%). From the result, it can be understood that purification by repetition of the conventional method merely results in gradual decrease of the recovery, and it is difficult to obtain a product of a high purity, i.e., 99.9% or higher.

Claims

1. A method for purification of 3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid, which comprises the step of recrystallizing said compound by using a solvent consisting essentially of an alcohol.
2. The method for purification according to claim 1, wherein the compound is (2E,4E,6E,10E)-3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid.
3. The method for purification according to claim 1 or 2, wherein the solvent is an alcohol.
4. The method for purification according to claim 3, wherein the alcohol is methanol.
5. The method for purification according to claim 1 to claim 4, wherein a purity of the compound after the purification step is 99.9% or higher.

Patentansprüche

1. Verfahren zur Reinigung von 3, 7, 11, 15-Tetramethyl-2, 4, 6, 10, 14-hexadecapentansäure, umfassend den Schritt des Rekristallisierens der Verbindung unter Verwendung eines Lösungsmittels, das im Wesentlichen aus einem Alkohol besteht.
2. Verfahren zur Reinigung gemäß Anspruch 1, wobei die Verbindung (2E, 4E, 6E, 10E)-3, 7, 11, 15-Tetramethyl-2, 4, 6, 10, 14-hexadecapentansäure ist
3. Verfahren zur Reinigung gemäß Anspruch 1 oder 2, wobei das Lösungsmittel ein Alkohol ist.
4. Verfahren zur Reinigung gemäß Anspruch 3, wobei der Alkohol Methanol ist.

5. Verfahren zur Reinigung nach den Ansprüchen 1 bis 4, wobei die Reinheit der Verbindung nach dem Reinigungsschritt 99,9% oder höher ist.

5 **Revendications**

1. Procédé pour la purification de l'acide 3,7,11,15-tétraméthyl-2,4,6,10,14-hexadécapentaénoïque, qui comprend l'étape de recristallisation dudit composé par utilisation d'un solvant consistant essentiellement en un alcool.
- 10 2. Procédé pour la purification suivant la revendication 1, dans lequel le composé est l'acide (2E,4E,6E,10E)-3,7,11,15-tétraméthyl-2,4,6,10,14-hexadécapentaénoïque.
3. Procédé pour la purification suivant la revendication 1 ou 2, dans lequel le solvant est un alcool.
- 15 4. Procédé pour la purification suivant la revendication 3, dans lequel l'alcool est le méthanol.
5. Procédé pour la purification suivant la revendication 1 à la revendication 4, dans lequel la pureté du composé après l'étape de purification est de 99,9% ou plus.

20

25

30

35

40

45

50

55